Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Authors:
Top Cited Papers
Open Access
- 1 April 2023
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 29 (2) , 206-216
Abstract
Liver cancer is the fourth most prevalent and the second most lethal cancer in China. Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma (HCC). Liver ultrasonography plus alpha-fetoprotein every 6 months continues to be the predominant surveillance modality. The age-Male-ALBI-Platelets score was recommended in the recent 2022 Chinese guidelines to predict HCC occurrence. The Chinese liver cancer (CNLC) staging system proposed in the 2017 guidelines continues to be the standard model for staging with modifications in the treatment allocations. Considering the aggressive nature of HBV-associated HCC, multimodal and high-intensity strategies like the addition of immunotherapy-based systemic treatment to local therapies, including resection, ablation, and intra-arterial therapies, have been adopted in real-life practices in China. The latest Chinese guidelines recommend atezolizumab plus bevacizumab, suntilimab plus a bevacizumab analog, lenvatinib, sorafenib, donafenib, and FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy as first-line treatment without priority. Regorafenib, apatinib, camrelizumab, and tislelizumab have been added as second-line systemic therapies for patients who progressed on sorafenib. Systemic therapies adopted in real-life practice are sophisticated with various combination modalities and different sequences.Keywords
Funding Information
- National Natural Science Foundation of China (82130077, 82090053, 81961128025)
- Science and Technology Commission of Shanghai Municipality (21JC1410100, 21JC1401200, 20JC1418900)
This publication has 89 references indexed in Scilit:
- Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized TrialJournal of Clinical Oncology, 2013
- Sirolimus-Based Immunosuppression in Liver Transplantation for Hepatocellular CarcinomaLiver Transplantation, 2012
- Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular CarcinomaJournal of Clinical Oncology, 2011
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tablesJournal of Clinical Epidemiology, 2011
- Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccinationVaccine, 2009
- Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, ChinaJournal of Cancer Research and Clinical Oncology, 2009
- Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patientsWorld Journal of Gastroenterology, 2009
- Steroid Avoidance in Liver Transplantation: Meta-Analysis and Meta-Regression of Randomized TrialsLiver Transplantation, 2008
- Novel advancements in the management of hepatocellular carcinoma in 2008Journal of Hepatology, 2008
- Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)Journal of Gastroenterology, 2003